title: Mucosal pharmacokinetics and pilot study of short course of parenteral imipenem in the eradication of Helicobacter pylori.
abstract: Eradication of Helicobacter pylori infection is known to reduce the incidence of duodenal ulcer recurrence. The most commonly used regimen for H. pylori infection is triple antimicrobial therapy for 1-2 weeks. This treatment is associated with frequent side effects and hence unsatisfactory compliance. As in vitro data showed that H. pylori is sensitive to imipenem, the pharmacokinetics of this drug in the gastric milieu, and the clinical efficacy of imipenem with omeprazole in eradicating H. pylori infection were studied. Imipenem/cilastatin levels in serum, gastric secretion and gastric mucosa were assayed in four patients after intravenous injection of a bolus dose of 500 mg. The serum and gastric secretion levels of imipenem achieved were more than 10 times the minimum inhibitory concentration of the drug for H. pylori. Gastric mucosal levels of imipenem vary considerably with time, which probably indicates rapid elimination of the drug into the gastric lumen. In the second part of this study, imipenem/cilastatin was given intravenously for the first 2 days after diagnosis of H. pylori infection in patients with endoscopically confirmed duodenal ulcers. The patients were also treated with 4 weeks of omeprazole. Clearance of H. pylori was initially achieved at the end of 2 days in 20 out of 22 (91%) patients. However, when the biopsies were repeated at 8 weeks, recurrence of H. pylori infection was evident in 19 cases (86.3%) indicating a failure of eradication. It was concluded that imipenem/cilastatin in combination with omeprazole failed to eradicate H. pylori infection.
authors.affiliation: Department of Medicine, Prince of Wales Hospital, Chinese University of Hong Kong, Shatin.
authors.forename: J J
authors.initials: JJ
authors.lastname: Sung
authors.forename: S C
authors.initials: SC
authors.lastname: Chung
authors.forename: S W
authors.initials: SW
authors.lastname: Hosking
authors.forename: R C
authors.initials: RC
authors.lastname: Chan
authors.forename: T K
authors.initials: TK
authors.lastname: Ling
authors.forename: M Y
authors.initials: MY
authors.lastname: Yung
authors.forename: A F
authors.initials: AF
authors.lastname: Cheng
authors.forename: A K
authors.initials: AK
authors.lastname: Li
mesh_terms: D001706:Biopsy; D002851:Chromatography, High Pressure Liquid; D015377:Cilastatin / Q000493:pharmacokinetics* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004381:Duodenal Ulcer / Q000188:drug therapy / Q000378:metabolism*; D004384:Duodenoscopy; D005500:Follow-Up Studies; D005750:Gastric Juice / Q000378:metabolism; D005753:Gastric Mucosa / Q000378:metabolism*; D016481:Helicobacter Infections / Q000188:drug therapy / Q000378:metabolism*; D016480:Helicobacter pylori / Q000187:drug effects*; D006801:Humans; D015378:Imipenem / Q000493:pharmacokinetics* / Q000627:therapeutic use; D007275:Injections, Intravenous; D010865:Pilot Projects
chemical_list: D015377:Cilastatin; D015378:Imipenem